Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study

[1]  D. Alberts,et al.  Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. , 2005, Gynecologic oncology.

[2]  R. Burger,et al.  Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Burger,et al.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Sood,et al.  Docetaxel Versus Paclitaxel for Adjuvant Treatment of Ovarian Cancer: Case–Control Analysis of Toxicity , 2004, American journal of clinical oncology.

[5]  Roger B. Lee,et al.  Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. , 2003, Gynecologic oncology.

[6]  J. Sorosky,et al.  Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Swenerton,et al.  Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Dimopoulos,et al.  Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. , 2000, Gynecologic oncology.

[9]  W. Curran,et al.  Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. , 2000, International journal of radiation oncology, biology, physics.

[10]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[11]  M. van Glabbeke,et al.  Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Lissoni,et al.  Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  P. Rose,et al.  A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.

[14]  D. Mutch,et al.  A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.

[15]  M. Bissery,et al.  Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. , 1995, Anti-cancer drugs.

[16]  G. Sutton,et al.  Phase II study of Ifosfamide and Mesna in refractory adenocarcinoma of the endometrium , 1994, Cancer.

[17]  H. Muss,et al.  Echinomycin in Recurrent and Metastatic Endometrial Carcinoma: A Phase II Trial of the Gynecologic Oncology Group , 1993, American journal of clinical oncology.

[18]  B. Cheson,et al.  Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Muss,et al.  Teniposide (VM‐26) in Patients with Advanced Endometrial Carcinoma A Phase II Trial of the Gynecologic Oncology Group , 1991, American journal of clinical oncology.

[20]  R. Mortel,et al.  Aminothiadiazole (NSC 4728) in Patients with Advanced Carcinoma of the Endometrium: A Phase II Study of the Gynecologic Oncology Group , 1990, American journal of clinical oncology.

[21]  G. Sutton,et al.  Phase II trial of cisplatin as first‐line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study , 1989, Gynecologic oncology.

[22]  G. Sutton,et al.  Phase II trial of clsplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A gynecologic oncology group study , 1989 .

[23]  P. Disaia,et al.  A Phase II Clinical Trial of Diaziquone in the Treatment of Patients with Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study , 1988, American journal of clinical oncology.

[24]  J. Thigpen,et al.  Phase II Trial of Piperazinedione in the Treatment of Advanced or Recurrent Endometrial Carcinoma A Gynecologic Oncology Group Study , 1986, American journal of clinical oncology.

[25]  L. Twiggs,et al.  ICRF‐159 (Razoxane) in Patients with Advanced Adenocarcinoma of the Endometrium A Gynecologic Oncology Group Study , 1986, American Journal of Clinical Oncology.

[26]  L. Lagasse,et al.  Phase II trial of cisplatin as second‐line chemotherapy in patients with advanced or recurrent endometrial carcinoma A Gynecologic Oncology Group study , 1984, American journal of clinical oncology.

[27]  J. Blessing,et al.  Phase II evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma: a Gynecologic Oncology Group Study. , 1983, Cancer treatment reports.

[28]  J. Blessing,et al.  Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. , 1982, Cancer treatment reports.

[29]  C. Cohen,et al.  Treatment of advanced endometrial adenocarcinoma with cis-dichlorodiammine platinum (II) after intensive prior therapy. , 1980, Gynecologic oncology.

[30]  M. Nooij,et al.  Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. , 2003, European journal of cancer.

[31]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.